ACLX - Arcellx - Stock Price & Dividends

Arcellx, Inc. is a biotechnology company that focuses on developing innovative immunotherapies to treat patients with cancer and other incurable diseases. The company's primary goal is to create life-changing treatments that address significant unmet medical needs.

At the forefront of Arcellx's pipeline is anitocabtagene autoleucel, a lead ddCAR product candidate currently in Phase 2 clinical trials for the treatment of relapsed or refractory multiple myeloma (rrMM). This promising therapy has the potential to improve treatment outcomes for patients with this aggressive blood cancer.

In addition to anitocabtagene autoleucel, Arcellx is developing a range of other product candidates, including ACLX-001, which is in Phase 1 clinical trials targeting BCMA to treat rrMM. The company is also advancing ACLX-002, which is in Phase 1 clinical trials targeting CD123 for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Furthermore, Arcellx has a preclinical product, ACLX-003, in development for the treatment of AML and MDS.

Beyond its hematological cancer programs, Arcellx is also exploring the development of product candidates for solid tumor programs, with the aim of expanding its pipeline to address a broader range of cancer types.

Arcellx has established a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel, leveraging the expertise and resources of both companies to accelerate the development of this promising therapy.

Founded in 2014 and headquartered in Redwood City, California, Arcellx, Inc. (formerly known as Encarta Therapeutics, Inc.) is a cutting-edge biotechnology company dedicated to improving the lives of patients with cancer and other serious diseases. For more information, please visit https://www.arcellx.com.